Jeffrey A. Morgan - Concepedia

Author

Jeffrey A. Morgan

Also Known As

Calif, J A Morgan, J Morgan, J. A. Morgan, J. Morgan, J.A Morgan, J.A. Morgan, JEFFREY A. MORGAN, Jaclynn Morgan, Jeffrey A Morgan

379

Publications

15K

Citations

H-Index

136

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Brigham and Women's Hospital Henry Ford Hospital Baylor College of Medicine

About

Jeffrey A. Morgan is an author at Dana-Farber Cancer Institute specializing in medicine, cardiology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	87	10K
2	Health Sciences	11	14	1.1K
3	Public Health	9	9	391
4	Engineering	2	2	131
5	Nursing	1	1	23

Jeffrey A. Morgan

135

Publications

13.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial George D. Demetri, Allan T. van Oosterom, Christopher R. Garrett, The Lancet Gastrointestinal OncologyMedicinePathologyColorectal CancerCancer Treatment	2006	2.6K
The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: Executive summary David S. Feldman, Salpy V. Pamboukian, Jeffrey J. Teuteberg, The Journal of Heart and Lung Transplantation Transplantation SurgeryAssisted CirculationTransplantationCardiovascular DiseaseMedicine	2013	1.4K
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Tammy F. Chu, Maria A. Rupnick, Risto Kerkelä, The Lancet MedicineCardiovascular PharmacologyPharmacotherapyCardiovascular ToxicityPharmacology	2007	1.1K
Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors Chandrajit P. Raut, Matthew Posner, Jayesh Desai, Journal of Clinical Oncology	2006	446
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors Jayesh Desai, Leila Yassa, Ellen Marqusee, Annals of Internal Medicine	2006	400
Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors Andrew J. Wagner, Izabela Malinowska-Kołodziej, Jeffrey A. Morgan, Journal of Clinical Oncology Malignant DiseaseMtor InhibitionMedicinePharmacologyImmunology	2010	389
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Suzanne George, Jean‐Yves Blay, Paolo G. Casali, European Journal of Cancer Surgical OncologySunitinib MalateGastrointestinal OncologyImatinib FailureMedicine	2009	365
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas Suzanne George, Priscilla Merriam, Robert G. Maki, Journal of Clinical Oncology Malignant DiseaseGastrointestinal OncologyMedicinePharmacologyDisease Control	2009	315
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial Suzanne George, Qian Wang, Michael C. Heinrich, Journal of Clinical Oncology	2012	245
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study Eytan Ben‐Ami, Constance M. Barysauskas, Sarah Solomon, Cancer	2017	215

Page 1